Identification of small molecule inhibitors of p27Kip1 ubiquitination by high-throughput screening

Cancer Science

Volumn 104, Issue 11, 2013, Pages 1461-1467

  Ooi, Li Ching ^a,b   Watanabe, Nobumoto ^a,b   Futamura, Yushi ^a   Sulaiman, Shaida Fariza ^b   Darah, Ibrahim ^b   Osada, Hiroyuki ^a,b  

^a RIKEN   (Japan)

^b SCHOOL OF PHYSICS   (Malaysia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CRYSTAL VIOLET; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; FLUORESCENT DYE; LINICHLORIN A; S PHASE KINASE ASSOCIATED PROTEIN 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL STRAIN 3T3; CONTROLLED STUDY; DRUG IDENTIFICATION; HELA CELL; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; UBIQUITINATION;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; DRUG SCREENING ASSAYS, ANTITUMOR; GENTIAN VIOLET; HELA CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MICE; MOLECULAR SEQUENCE DATA; NIH 3T3 CELLS; PEPTIDE FRAGMENTS; PROTEIN STABILITY; PROTEOLYSIS; SESQUITERPENES; SMALL MOLECULE LIBRARIES; UBIQUITINATION;

EID: 84886769857     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12246     Document Type: Article

References (50)

1. Sherr CJ, Roberts JM. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 1995; 9: 1149-63.
2. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999; 13: 1501-12.
3. Chu IM, Hengst L, Slingerland JM. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 2008; 8: 253-67.
4. Polyak K, Kato JY, Solomon MJ et al. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell-cycle arrest. Genes Dev 1994; 8: 9-22.
5. Slingerland JM, Hengst L, Pan CH, Alexander D, Stampfer MR, Reed SI. A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor β-arrested epithelial cells. Mol Cell Biol 1994; 14: 3683-94.
6. Slingerland J, Pagano M. Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol 2000; 183: 10-7.
7. Catzavelos C, Bhatacharya N, Ung YC et al. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 1997; 3: 227-30.
8. Coats S, Flanagan WM, Nourse J, Roberts JM. Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle. Science 1996; 272: 877-80.
9. Hengst L, Reed SI. Translational control of p27Kip1 accumulation during the cell cycle. Science 1996; 271: 1861-4.
10. Alessandrini A, Chiaur DS, Pagano M. Regulation of the cyclin-dependent kinase inhibitor p27 by degradation and phosphorylation. Leukemia 1997; 11: 342-5.
11. Pagano M, Tam SW, Theodoras AM et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995; 269: 682-5.
12. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998; 67: 425-79.
13. Carrano AC, Eytan E, Hershko A, Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1999; 1: 193-9.
14. Sutterluty H, Chatelain E, Marti A et al. p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Nat Cell Biol 1999; 1: 207-14.
15. Tsvetkov LM, Yeh KH, Lee SJ, Sun H, Zhang H. p27Kip1 ubiquitination and degradation is regulated by the SCFSkp2 complex through phosphorylated Thr187 in p27. Curr Biol 1999; 9: 661-4.
16. Nakayama K, Nagahama H, Minamishima YA et al. Targeted disruption of Skp2 results in accumulation of cyclin E and p27Kip1, polyploidy and centrosome overduplication. EMBO J 2000; 19: 2069-81.
17. Vlach J, Hennecke S, Amati B. Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27Kip1. EMBO J 1997; 16: 5334-44.
18. Sheaff RJ, Groudine M, Gordon M, Roberts JM, Clurman BE. Cyclin E-CDK2 is a regulator of p27Kip1. Genes Dev 1997; 11: 1464-78.
19. Montagnoli A, Fiore F, Eytan E et al. Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. Genes Dev 1999; 13: 1181-9.
20. Ganoth D, Bornstein G, Ko TK et al. The cell-cycle regulatory protein Cks1 is required for SCFSkp2-mediated ubiquitinylation of p27. Nat Cell Biol 2001; 3: 321-4.
21. Spruck C, Strohmaier H, Watson M et al. A CDK-independent function of mammalian Cks1: targeting of SCFSkp2 to the CDK inhibitor p27Kip1. Mol Cell 2001; 7: 639-50.
22. Nakayama K, Nagahama H, Minamishima YA et al. Skp2-mediated degradation of p27 regulates progression into mitosis. Dev Cell 2004; 6: 661-72.
23. Hershko DD. Oncogenic properties and prognostic implications of the ubiquitin ligase Skp2 in cancer. Cancer 2008; 112: 1415-24.
24. Yang G, Ayala G, De Marzo A et al. Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival. Clin Cancer Res 2002; 8: 3419-26.
25. Hershko D, Bornstein G, Ben-Izhak O et al. Inverse relation between levels of p27Kip1 and of its ubiquitin ligase subunit Skp2 in colorectal carcinomas. Cancer 2001; 91: 1745-51.
26. Gstaiger M, Jordan R, Lim M et al. Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci 2001; 98: 5043-8.
27. Latres E, Chiarle R, Schulman BA et al. Role of the F-box protein Skp2 in lymphomagenesis. Proc Natl Acad Sci 2001; 98: 2515-20.
28. Shim EH, Johnson L, Noh HL et al. Expression of the F-box protein SKP2 induces hyperplasia, dysplasia, and low-grade carcinoma in the mouse prostate. Cancer Res 2003; 63: 1583-8.
29. Sumimoto H, Yamagata S, Shimizu A et al. Gene therapy for human small-cell lung carcinoma by inactivation of Skp-2 with virally mediated RNA interference. Gene Ther 2005; 12: 95-100.
30. Kudo Y, Kitajima S, Ogawa I, Kitagawa M, Miyauchi M, Takata T. Small interferring RNA targeting of S phase kinase-interacting protein 2 inhibits cell growth of oral cancer cells by inhibiting p27 degradation. Mol Cancer Ther 2005; 4: 471-6.
31. Rico-Bautista E, Yang CC, Lu L, Roth GP, Wolf DA. Chemical genetics approach to restoring p27Kip1 reveals novel compounds with antiproliferative activity in prostate cancer cells. BMC Biol 2010; 8: 153.
32. Roy S, Kaur M, Agarwal C, Tecklenburg M, Sclafani RA, Agarwal R. p21 and p27 induction by silibinin is essential for its cell cycle arrest effect in prostate carcinoma cells. Mol Cancer Ther 2007; 6: 2696-707.
33. Chen Q, Xie W, Kuhn DJ et al. Targeting the p27 E3 ligase SCFSkp2 results in p27-and Skp2-mediated cell-cycle arrest and activation of autophagy. Blood 2008; 111: 4690-9.
34. Karasawa S, Araki T, Yamamoto-Hino M, Miyawaki A. A green-emitting fluorescent protein from Galaxeidae coral and its monomeric version for use in fluorescent labeling. J Biol Chem 2003; 278: 34167-71.
35. Mineo C, Murakami Y, Ishimi Y, Hanaoka F, Yamada M. Isolation and analysis of a mammalian temperature-sensitive mutant defective in G2 functions. Exp Cell Res 1986; 167: 53-62.
36. Yasuda H, Kamijo M, Honda R, Nakamura M, Hanaoka F, Ohba Y. A point mutation in C-terminal region of cdc2 kinase causes a G2-phase arrest in a mouse temperature-sensitive FM3A cell mutant. Cell Struct Funct 1991; 16: 105-12.
37. Osada H, Cui CB, Onose R, Hanaoka F. Screening of cell cycle inhibitors from microbial metabolites by a bioassay using a mouse cdc2 mutant cell line, tsFT210. Bioorg Med Chem 1997; 5: 193-203.
38. Hao B, Zheng N, Schulman BA et al. Structural basis of the Cks1-dependent recognition of p27Kip1 by the SCFSkp2 ubiquitin ligase. Mol Cell 2005; 20: 9-19.
39. Tomiki T, Saito T, Ueki M et al. RIKEN natural products encyclopedia.(RIKEN NPEdia), a chemical database of RIKEN natural products depository (RIKEN NPDepo). J Comp Aid Chem 2006; 7: 157-62.
40. Watanabe N, Sekine T, Takagi M et al. Deficiency in chromosome congression by the inhibition of Plk1 polo box domain-dependent recognition. J Biol Chem 2009; 284: 2344-53.
41. Moreira MP, Silva LM, Martins WK. The role of GADD45A in resistance to oxidative stress-mediated cell death in human colon tumor cell lines. Appl Cancer Res 2009; 29: 179-84.
42. Strohmaier H, Spruck CH, Kaiser P, Won KA, Sangfelt O, Reed SI. Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature 2001; 413: 316-22.
43. Kudo Y, Kitajima S, Sato S, Miyauchi M, Ogawa I, Takata T. High expression of S-phase kinase-interacting protein 2, human F-box protein, correlates with poor prognosis in oral squamous cell carcinomas. Cancer Res 2001; 61: 7044-7.
44. Esposito V, Baldi A, DeLuca A et al. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer. Cancer Res 1997; 57: 3381-5.
45. Loda M, Cukor B, Tam SW et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997; 3: 231-4.
46. Chiarle R, Budel LM, Skolnik J et al. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood 2000; 95: 619-26.
47. Gonzalez AG, Bermejo J, Amaro JM, Massanet GM, Galindo A, Cabrera I. Sesquiterpene lactones from Centaurea linifolia Vahl. Can J Chem 1978; 56: 491-4.
48. Docampo R, Moreno SNJ. The metabolism and mode of action of Gentian-Violet. Drug Metab Rev 1990; 22: 161-78.
49. Bornstein G, Bloom J, Sitry-Shevah D, Nakayama K, Pagano M, Hershko A. Role of the SCFSkp2 ubiquitin ligase in the degradation of p21Cip1 in S phase. J Biol Chem 2003; 278: 25752-7.
50. Tedesco D, Lukas J, Reed SI. The pRb-related protein p130 is regulated by phosphorylation-dependent proteolysis via the protein-ubiquitin ligase SCF(Skp2). Genes Dev 2002; 16: 2946-57.